Barry Ticho Sells 5,545 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 5,545 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total transaction of $170,065.15. Following the transaction, the insider owned 20,110 shares in the company, valued at $616,773.70. This trade represents a 21.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The stock was sold at an average price of $32.03, for a total transaction of $152,687.01.
• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $29.81 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $19.55 and a 1 year high of $40.22. The firm’s 50-day simple moving average is $31.17 and its 200-day simple moving average is $32.20. The firm has a market cap of $1.92 billion, a PE ratio of -8.93 and a beta of 1.23.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. On average, equities analysts predict that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research report on Friday, August 21st. They set an “overweight” rating and a $40.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 price target on the stock. Canaccord Genuity Group decreased their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Finally, Guggenheim reissued a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.25.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics during the fourth quarter worth about $26,000. Quantbot Technologies LP acquired a new position in Stoke Therapeutics during the 2nd quarter valued at about $34,000. KBC Group NV acquired a new position in Stoke Therapeutics during the 1st quarter valued at about $36,000. Harbour Investments Inc. grew its position in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Finally, Western Wealth Management LLC acquired a new stake in shares of Stoke Therapeutics in the first quarter valued at approximately $55,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.